A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in chronic lymphocytic leukemia.

Lachance, S; Christofides, A L; Lee, J K; Sehn, L H; Ritchie, B C; Shustik, C; Stewart, D A; Toze, C L; Haddad, E; Vinh, D C.

Afiliação

Lachance S; Université de Montréal, Montreal, QC;
Christofides AL; New Evidence, Toronto, ON;
Lee JK; Canadian Society of Allergy and Clinical Immunology, Toronto, ON;
Sehn LH; BC Cancer Agency, Vancouver, BC;
Ritchie BC; University of Alberta, Edmonton, AB;
Shustik C; McGill University Health Centre, Montreal, QC;
Stewart DA; Tom Baker Cancer Centre, Calgary, AB;
Toze CL; Leukemia/Bone Marrow Transplant Program of BC, Vancouver General Hospital, BC Cancer Agency, and University of British Columbia, Vancouver, BC;
Haddad E; chu Sainte-Justine, Departments of Pediatrics and of Microbiology, Immunology, and Infectiology, Université de Montréal, Montreal, QC.
Vinh DC; McGill University Health Centre, Montreal, QC;